Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso is the latest company with a bispecific to impress in a head-to-head study, this one for non-small cell lung cancer. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest data from Akeso’s ivonescimab, a VEGFxPD-1 bispecific antibody that went up against Keytruda pembrolizumab in one of its largest indications, first-line non-small cell lung cancer.The editors also discuss data from  Vaxcyte that the infectious disease company parlayed into the year’s largest follow-on financing and a new initiative by FDA veteran Janet Woodcock to bolster quality in biopharmas’ manufacturing. This episode of BioCentury This Week was sponsored by Parexel Biotech.View full story: https://www.biocentury.com/article/65350700:01 - Sponsor Message: Parexel Biotech01:39 - Akeso's Bispecific Challenge08:22 - Vaxcyte Pneumococcal Vaccine12:32 - Woodcock's Quality Initiative14:48 - Recap: The BioCentury Show on BiosimilarsReach us by sending a text

There are no comments yet.

Please log in to write the first comment.